PURE Bioscience, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PURE research report →
Price Chart
About the company
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company’s technology platform contains silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds.
- CEO
- Jeff Kitchell
- IPO
- 1996
- Employees
- 11
- HQ
- El Cajon, CA, US
Get TickerSpark's AI analysis on PURE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $7.80M
- P/E
- -2.80
- PEG
- 2.20
- P/S
- 3.37
- P/B
- -1.09
- EV/EBITDA
- -6.67
- Div Yield
- 0.00%
- Gross Margin
- 57.20%
- Op Margin
- -89.86%
- Net Margin
- -107.12%
- ROE
- 41.29%
- ROIC
- -1026.11%
Latest fiscal year · YoY change
- Revenue
- $2.32M+5.3%
- Gross Profit
- $1.33M+1.8%
- Op Income
- $-2,083,000
- Net Income
- $-2,483,000-3.5%
- EPS
- $-0.02+0.5%
- OCF Growth
- +13.7%
- FCF Growth
- +13.7%
- 52W High
- $0.10
- 52W Low
- $0.04
- 50D MA
- $0.07
- 200D MA
- $0.07
- Beta
- 0.22
- RSI (14)
- 40
- Avg Volume
- 28.64K
No earnings-call transcripts are available for PURE yet.
- Free Float
- 64.5%
- Shares Outstanding
- 130.02M
- Float Shares
- 83.86M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Goldman Capital Management Inc | 163.88K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 0 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 0 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 0 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 0 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 0 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 0 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 0 |
| Nov 17, 25 | Kitchell Jeffrey Scott | other | 0 |
| Aug 20, 24 | Myers Thomas Richard | other | 155,000 |
| Aug 20, 24 | Rendall David | other | 125,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PURE coverage
Recent articles, reports, and earnings notes.
No research on PURE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PURE report →Purecore Adds Jeremy S. Brett as Technical Advisor
globenewswire.com · Nov 5
Purecore Publishes Uranium Market Report Tracking AI-Driven Nuclear Demand
globenewswire.com · Oct 27
Purecore Closes $3.52M Oversubscribed Non-Brokered Private Placement
globenewswire.com · Oct 19
Purecore Upsizes Non-Brokered Private Placement to $3.5M
globenewswire.com · Oct 15
Purecore Announces Up to $2.5 Million Non-Brokered Private Placement
globenewswire.com · Oct 2
PURE Bioscience (OTCMKTS:PURE) Stock Price Crosses Above Two Hundred Day Moving Average – Time to Sell?
defenseworld.net · Sep 2
PURE HomeRiver Deepens Its Commitment to AppFolio to Power the Next Phase of Its Growth
globenewswire.com · Aug 26
Purecore Provides Corporate Update Highlighting Execution Across Uranium, Copper and Capital Markets
globenewswire.com · Aug 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.